Recently, Pudong innovative drug company Junshi Biologics announced that the National Drug Administration (NMPA) has accepted the supplementary application for the increase indication of Adalimumab injection (trade name: Junmaicang?) developed by the company in cooperation with M

2025/03/0723:32:36 regimen 1279
Recently, Pudong innovative drug company Junshi Biologics announced that the National Drug Administration (NMPA) has accepted the supplementary application for the increase indication of Adalimumab injection (trade name: Junmaicang?) developed by the company in cooperation with M - DayDayNews

Recently, Pudong innovative drug company - Junshi Biotechnology announced that National Drug Administration (NMPA) has accepted the supplementary application for the increase indication of the adalimumab injection (trade name: Junmaicang?) developed by the company in cooperation with Maiwei Biotechnology , to treat Crohn's disease , uveitis, multi-articular juvenile idiopathic arthritis , plaque psoriasis in children, and Crohn's disease in children.

tumor necrosis factor (TNF-α) is secreted by macrophages , mast cells and activated Th cells. It is a powerful inducer of the inflammatory response and a key regulator of innate immunity. It occupies a central position in the occurrence and development of multiple inflammations. TNF-α and TNF-α receptor binding can induce inflammatory responses. It has been proved that many autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, ankylosing spondylitis, is closely related to TNF-α. Anti-TNF-α monoclonal antibodies can bind to TNF-α receptors, reducing the immune response activated by TNF-α, thereby preventing inflammation.

Recently, Pudong innovative drug company Junshi Biologics announced that the National Drug Administration (NMPA) has accepted the supplementary application for the increase indication of Adalimumab injection (trade name: Junmaicang?) developed by the company in cooperation with M - DayDayNews

reporter learned that Junmaicang? has received major special support for the national "major new drug creation" science and technology project in the 12th Five-Year Plan. Previously, Junmaicang? has obtained NMPA approval indications including rheumatoid arthritis, ankylosing spondylitis and psoriasis.

As a biopharmaceutical company driven by innovation and committed to the discovery, development and commercialization of innovative therapies, Junshi Biologics has a rich R&D pipeline composed of more than 50 products under development, covering five major therapeutic areas, including malignant tumors, autoimmune system diseases, chronic metabolic diseases, neurological diseases and infectious diseases.

With the protein engineering core platform technology, Junshi Biosciences is at the forefront of international macromolecular drug research and development. It has obtained the first domestic anti-PD-1 monoclonal antibody marketing approval, the domestic anti-PCSK9 monoclonal antibody clinical application approval, and the world's first clinical application approval for the treatment of tumor anti-BTLA blocking antibodies in China and the US FDA. It is currently conducting a number of Ibhtml Phase 3/II clinical trials in China and the United States.

Editor in charge Yang Linyu

Author Yang Zhenying

Source Pudong release

regimen Category Latest News